BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 3, 2026
Home » Blogs » BioWorld MedTech Perspectives » Lack of awareness, education biggest obstacles to innovation

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Lack of awareness, education biggest obstacles to innovation

April 22, 2011
By Omar Ford

For nearly eight years my mother has been on anticoagulants. Because of this, she has to drive down to her local hospital every two weeks or so and clinicians test her blood to see if she is in danger of developing a blood clot.

In theory it seems pretty simple, and pretty painless. But in reality it can be pretty taxing. Although the visits last 20 minutes or so, my mother has had to plan her life around these “events.” Vacations have been cut short and travel plans now almost always include looking for an institution that will be able to test her blood, and send the information back to her doctors in a timely fashion.

If only we had known that there’s a simpler solution to all this. There is technology out there now that could allow patients like my mother take these test from home and send the results to their doctors.

The question then becomes, why aren’t we seeing more doctors push technologies such as this? Quite frankly, I think it comes down to an aspect that med-tech companies sometimes gloss over – the education piece.  

Companies need to have the sufficient capital to make education about their products, a stronger part of the post FDA approval piece. Now I’m just singling out this particular instance to make my point, but I wonder how many more patients out there are unaware of technology that could be beneficial to them. How many more patients are falling through the cracks because their doctors are unaware, or don’t have enough information to recommend a particular product.

Once I told my mother about the test, she was intrigued and she’s looking into the matter further.  I suspect it will take some discussion with her doctors before she is equipped with this new technology, but at least now she’s headed in the right direction and is finally aware of this life changing option.

Popular Stories

  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • Neurons

    AA meeting of minds as PTC, Novartis push votoplam in HD

    BioWorld
    What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
  • Nerves within a melanoma tumor

    Innervation can slow, as well as speed, tumor growth, study finds

    BioWorld
    Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
  • Glucagon-like peptide-1 receptor (GLP-1R) complex

    Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control

    BioWorld
    A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing